Stock Research for MEIP


Featured Broker: Ally Invest

Get the due diligence for another stock.


MEIP Stock Chart & Research Data

The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MEIP Due diligence Resources & Stock Charts

The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MEIP Detailed Price Forecast - CNN Money CNN View MEIP Detailed Summary - Google Finance
Yahoo View MEIP Detailed Summary - Yahoo! Finance Zacks View MEIP Stock Research & Analysis -

Stock Analysis

TradeIdeas View MEIP Trends & Analysis - Trade-Ideas Barrons View MEIP Major Holders - Barrons
NASDAQ View MEIP Call Transcripts - NASDAQ Seeking View MEIP Breaking News & Analysis - Seeking Alpha
Spotlight View MEIP Annual Report - OTC Report View MEIP OTC Short Report -
TradeKing View MEIP Fundamentals - TradeKing Charts View MEIP SEC Filings - Bar Chart
WSJ View Historical Prices for MEIP - The WSJ Morningstar View Performance/Total Return for MEIP - Morningstar
MarketWatch View the Analyst Estimates for MEIP - MarketWatch CNBC View the Earnings History for MEIP - CNBC
StockMarketWatch View the MEIP Earnings - StockMarketWatch MacroAxis View MEIP Buy or Sell Recommendations - MacroAxis
Bullish View the MEIP Bullish Patterns - American Bulls Short Pains View MEIP Short Pain Metrics -

Social Media Mentions

StockTwits View MEIP Stock Mentions - StockTwits PennyStocks View MEIP Stock Mentions - PennyStockTweets
Twitter View MEIP Stock Mentions - Twitter Invest Hub View MEIP Investment Forum News - Investor Hub
Yahoo View MEIP Stock Mentions - Yahoo! Message Board Seeking Alpha View MEIP Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MEIP - Insider Cow View Insider Transactions for MEIP - Insider Cow
CNBC View MEIP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MEIP - OTC Markets
Yahoo View Insider Transactions for MEIP - Yahoo! Finance NASDAQ View Institutional Holdings for MEIP - NASDAQ

Stock Charts

FinViz View MEIP Stock Insight & Charts - StockCharts View MEIP Investment Charts -
BarChart View MEIP Stock Overview & Charts - BarChart Trading View View MEIP User Generated Charts - Trading View

Latest Financial News for MEIP

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Posted on Monday December 03, 2018

The data demonstrate a 9% discontinuation rate due to adverse events, a substantially lower rate than observed in an earlier study, as well as an encouraging 36% complete response rate among patients receiving at least 6 cycles of treatment. The ongoing Phase 2 open-label study is evaluating a 45 mg dose of pracinostat in combination with azacitidine in order to improve safety/tolerability and retain patients in study longer than in an earlier Phase 2 study evaluating a 60 mg dose.

MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting
Posted on Sunday December 02, 2018

SAN DIEGO, Dec. 2, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that results from an ongoing Phase 1b study support the complementary potential of intermittent and continuous dosing schedules of ME-401, a selective phosphatidylinositol 3-kinase ("PI3K") delta inhibitor, to optimize the clinical risk-benefit ratio in patients with relapsed/refractory follicular lymphoma. The data announced today continue to support the rationale for MEI's planned Phase 2 study that evaluates both a continuous (CS) and intermittent (IS) dosing schedule of ME-401 as a means to enhance the drug candidate's clinical profile and thus potentially deliver improved benefits to patients. The Phase 2 study is expected to start around year-end and is intended to support MEI's accelerated approval registration strategy if successful.

MEI Pharma Presents Preclinical Data Demonstrating Voruciclib Synergistically Induces Apoptosis in Combination with Venetoclax in Acute Myeloid Leukemia Cells at the 2018 American Society of Hematology Annual Meeting
Posted on Saturday December 01, 2018

SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data presented at the 2018 American Society of Hematology (ASH) annual meeting demonstrating that voruciclib, MEI's orally available CDK9 inhibitor, synergistically induced apoptosis at clinically relevant concentrations when combined with venetoclax (marketed as Venclexta®) in human derived acute myeloid leukemia (AML) cells lines and patient samples. Voruciclib is currently being evaluated in a Phase 1b dose ranging study in patients with B-cell malignancies.

Is MEI Pharma Inc’s (NASDAQ:MEIP) CEO Paid At A Competitive Rate?
Posted on Friday November 30, 2018

Dan Gold became the CEO of MEI Pharma Inc (NASDAQ:MEIP) in 2010. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar

Stock Market & Investing Books

Enter a stock symbol to view the stock details.